SureTrader SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Anthera Pharmaceuticals, Inc. (ANTH)

ANTH RSS Feed
Add ANTH Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 1/5/2017 10:43:00 AM - Followers: 58 - Board type: Free - Posts Today: 0


 


 Anthera Pharmaceuticals Inc.     


                                              Nasdaq: ANTH


 

Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company has two product candidates in development.

 

Sollpura is Anthera’s novel biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

Blisibimod is Anthera’s BAFF inhibitor for the potential treatment of systemic lupus erythematosus and IgA nephropathy.


Pipeline



                            Contact Info                                                                           
                                                                           

Anthera Pharmaceuticals, Inc. 

25801 Industrial Blvd, Suite B • Hayward, CA 94545



Press Contact: [email protected]


Business Development: [email protected]


 Vendors: [email protected]


 Website: www.anthera.com

 

------>>Latest Developments<<-----

December 06, 2016

J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of Directors Paul F. Truex appointed as Executive Chairman of the Board Dr. Christopher Henney stepped down as Chairman ...

1
 
         
___________________________________________________________________________________________________________________________________________
Outstanding Share Data
October 31 ,2016,the Company had 41,955,126 common shares issued and outstanding
July 31,2016 the Company had 41,427,352 common shares issued and outstanding
April 27,2016 the Company had 40,987,145 common shares issued and outstanding
February 29,2016 the Company had 40,004,037 common shares issued and outstanding
November 1,2015 the Company had 39,875,405 common shares issued and outstanding
August 1,2015 the Company had 39,703,998 common shares issued and outstanding
May 1,2015 the Company had 35,816,364 common shares issued and outstanding
February 28,2015 the Company had 29,091,773 common shares issued and outstanding
November 10,2014 the Company had 22,939,553 common shares issued and outstanding
____________________________________________________________________________________________________________________________________________

MAJOR HOLDERS

 

68% of the outstanding owned by these longs

Outstanding 42mil minus Major ownership of 28.5mil = 13.5mil free trading float


28.5mil Major Holders in this,15mil Institutions,7.5mil Direct Holders,6mil Mutual Funds= 68% of 42mil os 


http://www.barrons.com/quote/stock/us/xnas/anth?mod=DNH_S

________________________________________________________________


http://finance.yahoo.com/q?s=ANTH

   Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation,

including cardiovascular and autoimmune diseases. We currently have a Phase 2 clinical program, blisibimod.It was just recently approved by FDA to move into

PHASE 3

 

   Blisibimod targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others.


  It has taken the lupus research community over 50 years to produce a new therapy. Although it is now a year old, Benlysta (belimumab),

now marketed by GlaxoSmithKline and Human Genome Sciences, is the first human monoclonal antibody for the treatment

of lupus.




  Benlysta had a slow take-off grossing $59.2 million in sales in the last three quarters of 2011, but it was approved in numerous

countries by year's end.
Estimated sales for Benlysta in 2012 are said to be about $230 million, with first annual profits likely by 2015.


  The surprisingly slow uptake of Benlysta allows for blisibimod to develop into a promising drug as

it currently has more desirable features than that of Benlysta.


Blisibimod has a dosing regimen of one injection weekly, compared to that of Benlysta which requires a

series of dosing before the maintenance dose begins. Also, Benlysta has limitations on usage pertaining to

specific patient populations and has not been studied in combination with other biologics.

These attributes of blisibimod including a different mechanism of action, will set it apart from

Benlysta, Global Data concludes.

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ANTH
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ANTH News: Current Report Filing (8-k) 01/06/2017 05:01:53 PM
ANTH News: Current Report Filing (8-k) 12/27/2016 05:00:35 PM
ANTH News: Anthera Announces the Phase 3 SOLUTION Study with Sollpura™ in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficie... 12/27/2016 04:05:00 PM
ANTH News: Anthera Pharmaceuticals Announces Continuation of SIMPLICITY Study of Sollpura™ Following Positive DMC Review 12/13/2016 08:30:00 AM
ANTH News: Statement of Changes in Beneficial Ownership (4) 12/08/2016 06:52:58 PM
PostSubject
#1986   out at .72 + on 1/3, back in Atlanta1 01/05/17 10:43:00 AM
#1985   Higher low's being set here. Looking good. GoHighOrGoHigh 01/04/17 12:26:09 PM
#1984   Bottom bounce? EquityElite 01/03/17 03:23:12 PM
#1983   Really bullish if it could turn this inside PAC 01/03/17 03:10:56 PM
#1982   trying to make a move here.. Atlanta1 01/03/17 03:03:15 PM
#1981   Nice. Been seeing it being accumulated. It'll bounce PAC 01/03/17 02:11:07 PM
#1980   in sub .68 this morning.. Atlanta1 01/03/17 02:10:10 PM
#1979   ANTH .68 inside day so far. let's try PAC 01/03/17 02:09:06 PM
#1978   * * $ANTH Video Chart 12-28-16 * * ClayTrader 12/28/16 04:58:25 PM
#1977   lol grow up, pal.. Atlanta1 12/28/16 04:18:33 PM
#1976   $ANTH ROFLMFAO $ANTH = pure retail garbage myopinion 12/28/16 04:15:22 PM
#1975   doubled up sub .70 Atlanta1 12/28/16 03:01:16 PM
#1974   $ANTH - in at .7058 Atlanta1 12/28/16 01:54:35 PM
#1973   problems? bad news? kurt_vdh 12/28/16 01:15:35 PM
#1972   Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Looks Good For A trendmkr 12/28/16 12:33:07 PM
#1971   ANTH .71 seeing it being soaked up. Think PAC 12/28/16 12:01:37 PM
#1970   .69 Buy the bad news and wait for shurtha2000 12/28/16 11:41:11 AM
#1969   Ouch, think it might rebound a bit or viper666 12/28/16 12:22:56 AM
#1968   Any comments from posters on upcoming data release? W&T Capital LLC 12/27/16 10:48:59 AM
#1967   Great news for Pharma stocks , ANTH is CoinOp 12/23/16 12:57:00 AM
#1966   Ebola vaccine is safe and effective, scientists declare yblood 12/22/16 10:00:48 PM
#1965   BTW Shortsqueeze data for ANTH has it at CoinOp 12/19/16 02:19:58 AM
#1964   We shall see , watching if ANTH generates CoinOp 12/19/16 02:01:48 AM
#1963   I noticed that surge also. Did some senderos 12/18/16 11:21:45 AM
#1962   BUY confirmed also on fri for the candlesticks, CoinOp 12/18/16 02:20:09 AM
#1961   Block trades/volume surge for ANTH end of day CoinOp 12/18/16 01:58:01 AM
#1960   Anthera Pharmaceuticals Announces Continuation of SIMPLICITY Study of senderos 12/13/16 09:17:55 AM
#1959   My previous thought really brings to light the CoinOp 12/10/16 01:27:41 AM
#1958   Nice article and we are in the hammer CoinOp 12/10/16 12:06:35 AM
#1957   Biotech Movers And Shakers: Cascadian Therapeutics and Anthera trendmkr 12/09/16 10:55:09 AM
#1956   Filing for ANTH out yesterday looks like $2 CoinOp 12/09/16 01:43:45 AM
#1955   Good news and new CEO steps up, just CoinOp 12/08/16 03:41:54 AM
#1954   Added starter position in ANTH today after some CoinOp 12/07/16 09:11:24 PM
#1953   * * $ANTH Video Chart 12-07-16 * * ClayTrader 12/07/16 04:51:49 PM
#1952   I have squashed this bug for the ANTH time. willlbone 11/30/16 03:23:56 PM
#1951   ANTH bearish 3.13 stocktrademan 08/19/16 04:48:17 PM
#1950   A burst on the opening to $4. Backed off Jacque_Strap 07/11/16 10:01:04 AM
#1949   Agreed. Let's see if if closes near $5 by the Jacque_Strap 07/10/16 06:41:13 PM
#1948   Looks like we might get a good run jimmy667 07/10/16 11:07:08 AM
#1947   Impressive price action while most hit the dirt jimmy667 06/26/16 03:31:18 PM
#1946   Anthera Craig Thompson, President and COO of $ANTH, to Paulieme 06/21/16 03:07:44 PM
#1945   ANTH bearish 3.02 stocktrademan 06/17/16 01:02:01 PM
#1944   5/9 earnings and updates on their pipeline. Would love Jacque_Strap 05/01/16 07:40:00 PM
#1943   Up over 11% today on above avg volume. Shareholders Jacque_Strap 04/21/16 09:28:06 PM
#1942   $ANTH recent news/filings stocktrademan 03/17/16 11:46:14 AM
#1941   Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Given Consensus Rating of Paulieme 03/04/16 12:31:30 AM
#1940   Rhenman & Partners Asset Management Has $1,160,000 Position Paulieme 02/25/16 06:06:32 PM
#1939   Anthera Pharmaceuticals Inc (ANTH) PT Lowered to $11.00 Paulieme 02/21/16 06:23:13 PM
#1938   Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH): Zacks Growth Score Paulieme 02/15/16 12:30:32 PM
#1937   Zacks: Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Given $13.33 Average Paulieme 02/09/16 02:06:49 PM
PostSubject